[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618308":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":11,"centralContacts":11,"locations":45,"responsibleParty":63,"collaborators":11,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":11,"overallStatus":89,"whyStopped":11,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Benha University","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Group D (Dexamethasone)","ACTIVE_COMPARATOR",null,[13],"Drug: Dexamethasone",{"label":15,"type":10,"description":11,"interventionNames":16},"Group X (Dexmedetomidine)",[17],"Drug: Dexmedetomidine",{"label":19,"type":10,"description":11,"interventionNames":20},"Group DX (Combination)",[21],"Drug: Dexamethasone and dexmedetomidine",{"label":23,"type":24,"description":11,"interventionNames":25},"Group P (Placebo)","PLACEBO_COMPARATOR",[26],"Drug: Placebo",[28,33,37,41],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","Dexamethasone","Participants will receive Dexamethasone 8 mg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.",[9],{"type":29,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"Dexmedetomidine","Participants will receive Dexmedetomidine 0.5 mcg \u002Fkg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.",[15],{"type":29,"name":38,"description":39,"armGroupLabels":40,"otherNames":11},"Dexamethasone and dexmedetomidine","Participants will receive Dexamethasone 8 mg IV + Dexmedetomidine 0.5 mcg\u002Fkg IV+ Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia",[19],{"type":29,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"Placebo","Participants will receive Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia",[23],[46],{"facility":47,"status":11,"city":48,"state":11,"zip":11,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Benha University Hospital","Banhā","Egypt","EG",{"type":52,"coordinates":53},"Point",[54,55],31.1842,30.45977,{"lat":55,"lon":54},[58],{"name":59,"role":60,"phone":61,"phoneExt":11,"email":62},"Taghreed Sakr, MD degree of anesthesia","CONTACT","00201112723187","taghreed.sakr@fmed.bu.edu.eg",{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Taghreed Elshahat Sakr","lecturer of anesthesia and icu","100618308","dexamethasone-dexmedetomidine-and-their-combination-on-post-op-git-function-measured-by-i-ffed-score-post-laparoscopic-cholecystectomy-100618308",false,"NCT07329933","Dexamethasone, Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy","Effect of Dexamethasone, Dexmedetomidine and Their Combination on Postoperative Gastrointestinal Function Measured by I-FEED Score After Elective Laparoscopic Cholecystectomy Surgery: a Randomized Controlled Trial","GIT","Inclusion Criteria:\n\n\\- . Age 18-65 years. 2. American Society of Anesthesiologists (ASA) physical status I or II. 3. Scheduled for elective laparoscopic cholecystectomy surgery under general anesthesia.\n\n4\\. Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or contraindication to any study drug (dexamethasone, dexmedetomidine, or placebo).\n\n  2\\. Pre-existing gastrointestinal motility disorders (e.g., gastroparesis, inflammatory bowel disease).\n\n  3\\. Chronic use of opioids, steroids, or antiemetics. 4. History of severe cardiac disease (e.g., high-grade AV block, severe bradycardia).\n\n  5\\. Uncontrolled diabetes mellitus (HbA1c \\> 8.0%). 6. Emergency surgery or conversion to open surgery. 7. Pregnancy or breastfeeding. 8. Morbid obesity (BMI \\>40). 9. Severe hepatic or renal dysfunction.","ALL","18 Years","65 Years",{"count":79,"type":80},160,"ESTIMATED","INTERVENTIONAL",[83],"NA","The goal of this clinical trial is to learn the effect of Dexamethasone and Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy\n\nWhat medical problems do participants have when taking Dexamethasone and Dexmedetomidine? Researchers will compare Dexamethasone and Dexmedetomidine and Their Combination to a placebo (a look-alike substance that contains no drug) to see the effect on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy Participants will receive Dexamethasone 8 mg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Dexmedetomidine 0.5 mcg \u002Fkg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Dexamethasone 8 mg IV + Dexmedetomidine 0.5 mcg\u002Fkg IV+ Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia",[86,87,30,34,88],"GIT Function","Cholecystectomy, Laparoscopic","I-FEED Score","NOT_YET_RECRUITING","2025-12-29",{"date":92,"type":93},"2026-01-09","ACTUAL",{"date":95,"type":80},"2025-12-15",{"date":97,"type":80},"2026-06-01",{"name":5,"class":6},1]